A股異動丨瑞普生物跌幅擴大至超15%,跌幅居市場首位
瑞普生物(300119.SZ)跌幅擴大至超15%,跌幅暫居市場首位,報22.3元,成交額放大至10億元,總市值104億元。消息上,2024年是疫苗行業開始分化的元年,陸續出現虧本的企業。TOP10企業中,易邦、科前、瑞普利潤位列前三,但整體利潤增速放緩,反映出價格戰對盈利能力的擠壓。有分析指,這一現象標誌着行業進入深度調整期,未來或將迎來大規模洗牌。新豬派調研顯示,2024年行業整體“增收不增利”,部分企業依賴規模效應勉強維持。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.